Stoke Therapeutics ( ($STOK) ) has released its Q3 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...

Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S.

CAMBRIDGE, Mass. and BEDFORD, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein ...

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome – ...

Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that ...

Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company’s market value has increased by approximately $3.3 billion over ...

Oct 1 (Reuters) - A California federal judge has determined that biotech company Biogen owes Roche's Genentech (ROG.S), opens new tab more than $88 million in patent royalties for sales of Biogen's ...